In addition, some teams have also explored bispecific CAR-T, such as targeting both TIM-3 and CD13, which demonstrated higher tumor clearance and relatively controllable toxicity to normal hematopoietic stem cells in AML mouse models (43). The gene discussed is HAVCR2; the disease is neoplasm.